Xeloda () vs Nerlynx (neratinib)
Xeloda () vs Nerlynx (neratinib)
Xeloda (capecitabine) is an oral chemotherapy drug that is commonly used to treat certain types of breast and colorectal cancer by interfering with the growth of cancer cells. Nerlynx (neratinib), on the other hand, is an oral tyrosine kinase inhibitor specifically designed to treat a certain kind of early-stage breast cancer that has a high chance of coming back and is HER2-positive, by blocking specific enzymes that promote cell growth. The choice between Xeloda and Nerlynx would depend on the specific characteristics and stage of the cancer, the presence of HER2 receptors, and the overall treatment plan determined by the healthcare provider.
Difference between Xeloda and Nerlynx
Metric | Xeloda () | Nerlynx (neratinib) |
---|---|---|
Generic name | Capecitabine | Neratinib |
Indications | Colorectal cancer, metastatic breast cancer | Early-stage breast cancer, extended adjuvant treatment of HER2-positive breast cancer |
Mechanism of action | Antimetabolite, thymidylate synthase inhibitor | Tyrosine kinase inhibitor |
Brand names | Xeloda | Nerlynx |
Administrative route | Oral | Oral |
Side effects | Hand-foot syndrome, diarrhea, nausea, vomiting, abdominal pain | Diarrhea, nausea, abdominal pain, fatigue, rash |
Contraindications | Dihydropyrimidine dehydrogenase (DPD) deficiency | Liver impairment, severe renal impairment |
Drug class | Antimetabolite, Fluoropyrimidine | Tyrosine kinase inhibitor |
Manufacturer | Roche | Puma Biotechnology |
Efficacy
Xeloda (Capecitabine) in Breast Cancer Treatment
Xeloda, also known by its generic name capecitabine, is an oral chemotherapy medication that is used in the treatment of breast cancer. It is a prodrug that is converted to 5-fluorouracil (5-FU) in the body, which is a cytotoxic agent that inhibits DNA synthesis and function, leading to cell death. The efficacy of Xeloda has been demonstrated in several clinical trials, particularly in patients with metastatic breast cancer. When used either as monotherapy or in combination with other drugs, Xeloda has shown to be effective in improving overall survival rates, delaying disease progression, and achieving partial or complete tumor responses in a significant number of patients.
Nerlynx (Neratinib) in Breast Cancer Management
Nerlynx, with the active ingredient neratinib, is an oral tyrosine kinase inhibitor that targets HER2-positive breast cancer, a subtype in which cancer cells have higher levels of the HER2 protein. The efficacy of Nerlynx has been primarily evaluated in the extended adjuvant treatment of HER2-positive early breast cancer. In clinical trials, Nerlynx has been shown to significantly reduce the risk of cancer recurrence when used following adjuvant trastuzumab therapy. This benefit is particularly notable in patients who have completed one year of trastuzumab, a standard treatment for HER2-positive breast cancer.
Comparative Efficacy in Different Settings
While both Xeloda and Nerlynx are used in the treatment of breast cancer, their application and efficacy differ based on the cancer's characteristics and the treatment setting. Xeloda is often used in metastatic settings and can be effective in HER2-negative breast cancer, while Nerlynx is specifically indicated for early-stage HER2-positive breast cancer in the extended adjuvant setting. The choice between these medications, or their use in combination with other treatments, depends on factors such as the stage of cancer, HER2 status, and previous treatments the patient has undergone.
Conclusion on Efficacy
In conclusion, both Xeloda and Nerlynx have shown efficacy in the treatment of breast cancer, albeit in different contexts and patient populations. Xeloda's role in metastatic breast cancer and its ability to improve survival and response rates make it a valuable option for patients with advanced disease. On the other hand, Nerlynx serves as an important treatment for reducing the risk of recurrence in early-stage HER2-positive breast cancer following initial therapy with trastuzumab. The use of these medications should be tailored to the individual patient's needs and should be guided by the oncologist's expertise in the light of the latest clinical evidence.
Regulatory Agency Approvals
Xeloda
Nerlynx
Access Xeloda or Nerlynx today
If Xeloda or Nerlynx are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us